Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 97 of 1,261
  1. US 12076409

    Polymer-drug conjugates for combination anticancer therapy

    The Regents of the University of California · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  2. US 12077760

    DNA aptamers and use thereof for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  3. US 12077612

    Peptide compositions

    RHYTHM PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  4. US 12076397

    Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  5. US 12077772

    Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  6. US 12077782

    Viral clearance by low pH hold

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  7. US 12076418

    Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

    ENGENE, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  8. US 12077515

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  9. US 12076324

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  10. US 12076328

    Pharmaceutical compositions of niclosamide

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  11. US 12077498

    C4-carboxylic acid-substituted tryptamine derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  12. US 12077540

    Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  13. US 12077502

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  14. US 12077507

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  15. US 12077587

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  16. US 12077506

    Indane derivatives as hypoxia inducible factor-2(α) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  17. US 12077555

    STAT degraders and uses thereof

    Kymera Therapeutics, Inc. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  18. US 12077543

    P2X3 and/or P2X2/3 compounds and methods

    Asana BioSciences, LLC · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  19. WO 2024175803

    COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES

    AB SCIENCE [FR] · Granted Aug 29, 2024 · Expires Aug 24, 2044

    granted
  20. US 12071434

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  21. US 12070472

    Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds

    The Board of Regents of the University of Texas System · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  22. US 12071468

    Purification of Factor VIII subspecies

    Takeda Pharmaceutical Company Limited · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  23. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Montefiore Medical Center · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  24. US 12070506

    Steroids and antibody-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.